KR960704578A - 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer) - Google Patents

모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)

Info

Publication number
KR960704578A
KR960704578A KR1019960701610A KR19960701610A KR960704578A KR 960704578 A KR960704578 A KR 960704578A KR 1019960701610 A KR1019960701610 A KR 1019960701610A KR 19960701610 A KR19960701610 A KR 19960701610A KR 960704578 A KR960704578 A KR 960704578A
Authority
KR
South Korea
Prior art keywords
lactate
reservoir
mixture
drug
skin
Prior art date
Application number
KR1019960701610A
Other languages
English (en)
Inventor
리나 톨먼 타스코비치
수 일 염
은 수 이
니베스 마르잔 크리솔로고
Original Assignee
에드워드 엘. 만델
앨자 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에드워드 엘. 만델, 앨자 코포레이션 filed Critical 에드워드 엘. 만델
Publication of KR960704578A publication Critical patent/KR960704578A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

투여될 약물의 치료 유효량; 및 모노글리세리드 또는 모노글리세리드의 혼합물, 및 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 투과-촉진 혼합물의 조합으로 이루어지는 체표면이나 막을 통한 투과에 의해 약물을 투여하기 위한 체표면 또는 막에 작용하는 물질의 조성물.

Description

모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (46)

  1. (a) 투여될 약물의 치료 유효량 및 (b) (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 투과-촉진 혼합물의 조합으로 이루어지는 체표면이나 막을 통한 투과에 의해 약물을 투여하기 위한 체표면 또는 막에 작용하는 물질의 조성물.
  2. 제1항에 있어서, 모노글리세리드 또는 모노글리세리드의 혼합물이 조성물의 20중량%를 이루며, 락테이트 에스테르 또는 락테이트 에스테르의 혼합물이 조성물의 12중량%를 이루는 것인 조성물.
  3. 제1항에 있어서, 락테이트 에스테르가 라우릴 락테이트인 조성물.
  4. 제1항에 있어서, 락테이트 에스테르가 에틸 락테이트인 조성물.
  5. 제1항에 있어서, 락테이트 에스테르가 미리스틸 락테이트인 조성물.
  6. 제1항에 있어서, 락테이트 에스테르가 세틸 락테이트인 조성물.
  7. 제1항에 있어서, 락테이트 에스테르의 혼합물이 에틸 락테이트 및 라우릴 락테이트인 조성물.
  8. 제3 내지 7항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 조성물.
  9. 제8항에 있어서, 글리세롤 모노라우레이트가 조성물의 20중량%를 이루며, 락테이트 에스테르가 조성물의 12중량%를 이루는 것인 조성물.
  10. 제1항에 있어서, 약물이 벤조디아제핀, 항무스카린 제제, 부신피질 스테로이드, 에스트로겐, 안드로겐 또는 프로게스틴으로 이루어지는 군으로부터 선택되는 것인 조성물.
  11. 제10항에 있어서, 부신피질 스테로이드가 알클로메타존, 알도스테론, 암시노니드, 베클로메타존, 디프로피오네이트, 베타메타존, 클로베타졸, 클로코르톨론, 코르티졸, 코르티존, 코르티코스테론, 데소니드, 데속시메타존, 11-데속시코르티코스테론, 11-데속시코르티졸, 덱사메타존, 디플로라존, 플루드로코르티존, 플루니솔리드, 플루오시놀론, 플루오시노니드, 플루오메톨론, 플루르안드레놀리드, 할시노니드, 히드로코르티존, 메드리존, 6α-메틸프레드니졸론, 모메타존, 파라메타존, 프레드니졸론, 프레드니존, 테트라히드로코르티졸 또는 트리암시놀론으로 이루어지는 군으로부터 선택되는 것인 조성물.
  12. 제10항에 있어서, 안드로겐이 다나졸, 플루옥시메스테론, 메트안드로스테놀론, 메틸테르토스테론, 난드롤론 데카노에이트, 난드롤론 펜프로피오네이트, 옥산드롤론, 옥시메톨론, 스타노졸론, 테스톨락톤, 테스토스테론, 테스토스테론 시피오네이트, 테스토스테론 에난테이트 또는 테스토스테론 프로피오네이트로 이루어지는 군으로부터 선택되는 것인 조성물.
  13. 제10항에 있어서, 에스트로겐이 클로로트리아니센, 디에틸스틸베스트롤, 에스트라디올, 에스트라디올 시피오네이트, 에스트라디올 발러레이트, 에스토론, 황산나트륨 에스트론, 에스트로피페이트, 에티닐 에스트라디올, 메스트라놀, 퀸에스트롤 또는 나트륨 이퀄린 술페이드로 이루어지는 군으로부터 선택되는 것인 조성물.
  14. 제10항에 있어서, 프로게트틴이 에티노디올 디아세테이트, 게스토덴, 히드록시프로게스테론 카프로에이트, 레보노르게스트렐, 메드록시프로게스테론 아세테이트, 메게스트롤 아세테이트, 노르에틴드론, 노르에틴드론 아세테이트, 노르에티노드렐, 노르게스트렐 또는 프로게스테론으로 이루어지는 군으로부터 선택되는 것인 조성물.
  15. 제10항에 있어서, 항무스카린 제제가 아니소트로핀, 아트로핀, 클리디늄, 시클로펜톨레이트, 디시클로민, 플라복세이트, 글리코피롤레이트, 헥소시클륨, 호마트로핀, 이프라트로퓸, 이소프로프아미드, 메펜졸레이트, 메탄텔린, 옥시펜시클리민, 피렌제핀, 프로판텔린, 스코폴아민, 텔렌제핀, 트리디헥스에틸 또는 트로픽 아미드로 이루어지는 군으로부터 선택되는 것인 조성물.
  16. (a) 치료 유효량의 약물 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는, 치료 유효 속도에서의 약물의 경피 투여용 장치.
  17. (a) 치료 유효량의 약물 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 제1저장고; (b) 과량의 투과 촉진 혼합물 및 포화 이하의 약물로 이루어지는 제2저장고; (c) 제1저장고 및 제2저장고 사이의 속도-조절막; (d) 저장고의 피부 반대편 상의 배면; 및 (e) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루지는, 치료 유효 속도에서의 약물의 경피 투여용 장치.
  18. 제16 또는 17항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 장치.
  19. 제16 또는 17항에 있어서, 락테이트 에스테르가 라우릴 락테이트인 장치.
  20. 제16 또는 17항에 있어서, 락테이트 에스테르가 에틸 락테이트인 장치.
  21. 제16 또는 17항에 있어서, 락테이트 에스테르가 세틸 또는 미리스틸 락테이트인 장치.
  22. 제16 또는 17항에 있어서, 락테이트 에스테르의 혼합물이 에틸 및 라우릴 락테이트인 장치.
  23. 제16 또는 17항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며, 락테이트 에스테르가 에틸 락테이트 또는 라우릴 락테이트 또는 그의 혼합물인 장치.
  24. 제16 또는 17항에 있어서, 약물이 벤조디아제핀, 항무스카린 제제, 에스트로겐, 안드로겐 또는 프로게스틴으로 이루어지는 군으로부터 선택되는 것인 장치.
  25. 제16 또는 17항에 있어서, 약물이 알클로메타존, 알도스테론, 암시노니드, 베클로메타존, 디프로피오네이트, 베타메타존, 클로베타졸, 클로코르톨론, 코르티졸, 코르티존, 코르티코스테론, 데소니드, 데속시메타존, 11-데속시코르티코스테론, 11-데속시코르티졸, 덱사메타존, 디플로라존, 플루드로코르티존, 플루니솔리드, 플루오시놀론, 플루오시노니드, 플루오메톨론, 플루르안드레놀리드, 할시노니드, 히드로코르티존, 메드리존, 6α-메틸프레드니졸론, 모메타존, 파라메타존, 프레드니졸론, 프레드니존, 테트라히드로코르티졸 또는 트리암시놀론으로 이루어지는 군으로부터 선택되는 것인 장치.
  26. 제16 또는 17항에 있어서, 약물이 다나졸, 플루옥시메스테론, 메트안드로스테놀론, 메틸테르토스테론, 난드롤론 데카노에이트, 난드롤론 펜프로피오네이트, 옥산드롤론, 옥시메톨론, 스타노졸론, 테스톨락톤, 테스토스테론, 테스토스테론 시피오네이트, 테스토스테론 에난테이트 또는 테스토스테론 프로피오네이트로 이루어지는 군으로부터 선택되는 것인 장치.
  27. 제16 또는 17항에 있어서, 약물이 클로로트리아니센, 디에틸스틸베스트롤, 에스트라디올, 에스트라디올 시피오네이트, 에스트라디올 발러레이트, 에스토론, 황산 나트륨 에스트론, 에스트로피페이트, 에티닐 에스트라디올, 메스트라놀, 퀸에스트롤 또는 나트륨 이퀄린 술페이드로 이루어지는 군으로부터 선택되는 것인 장치.
  28. 제16 또는 17항에 있어서, 프로게트틴이 에티노디올 디아세테이트, 게스토덴, 히드록시프로게스테론 카프로에이트, 레보노르게스트렐, 메드록시프로게스테론 아세테이트, 메게스트롤 에세테이트, 노르에틴드론, 노르에틴드론 아세테이트, 노르에티노드렐, 노르게스트렐 또는 프로게스테론으로 이루어지는 군으로부터 선택되는 것인 장치.
  29. 제16 또는 17항에 있어서, 약물이, 아니소트로핀, 아트로핀, 클리디늄, 시클로펜톨레이트, 디시클로민, 플라복세이트, 글리코피롤레이트, 헥소시클륨, 호마트로핀, 이프라트로퓸, 이소프로프아미드, 메펜졸레이트, 메탄텔린, 옥시펜시클리민, 피렌제핀, 프로판텔린, 스코폴아민, 텔렌제핀, 트리디헥스에틸 또는 트로픽아미드로 이루어지는 군으로부터 선택되는 것인 장치.
  30. 제16항에 있어서, 저장고와 피부 사이의 관계를 유지시켜주는 수단이 저장고의 피부 인접면 상의 인-라인(in-line) 접착층으로 이루어지는 것인 장치.
  31. 제17항에 있어서, 저장고와 피부 사이의 관계를 유지시켜주는 수단이 제1저장고의 피부 인접면 상의 인-라인(in-line) 접착층으로 이루어지는 것인 장치.
  32. 제17항에 있어서, 제1저장고 또한 저장고와 피부 사이의 관계를 유지시켜주는 수단으로서 기능하는 접착층인 장치.
  33. 제19 내지 22항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 장치.
  34. 제33항에 있어서, 글리세롤 모노라우레이트 및 락테이트 에스테르가 약물 함유 저장고의 각각 20중량% 및 12중량%를 이루는 것인 장치.
  35. (a) 연장된 시간 주기 동안 치료 효과를 제공하기에 충분한 양의 약물 및 피부 투과-촉진량의 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루어지는 경피 전달 장치를 환자의 피부 상에 올려 놓는 단계로 이루어지는 약물의 경피 투여 방법.
  36. (a) 연장된 시간 주기 동안 치료 효과를 제공하기에 충분한 양의 약물 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 저장고; (b) 저장고의 피부 반대편 상의 배면; 및 (c) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루지는 경피 약물 전달 장치를 환자의 피부 상에 올려 놓는 단계로 이루어지는 약물의 경피 투여 방법.
  37. (a) 치료 유효량의 약물 및 (ⅰ) 15 내지 25중량%의 모노글리세리드 또는 모노글리세리드의 혼합물 및 (ⅱ) 8 내지 25중량%의 락테이트 에스테르 또는 락테이트 에스테르의 혼합물로 이루어지는 피부 투과-촉진량의 투과 혼합물로 이루어지는 제1저장고; (b) 과량의 투과 촉진 혼합물 및 포화 이하의 약물로 이루어지는 제2저장고; (c) 제1저장고 및 제2저장고 사이의 속도-조절막; (d) 저장고의 피부 반대편 상의 배면; 및 (e) 저장고를 피부와의 약물- 및 투과 촉진 혼합물-이동 관계로 유지시켜 주는 수단으로 이루지는 경피 전달 장치를 환자의 피부 상에 올려 놓는 단계로 이루어지는 약물의 경피 투여 방법.
  38. 제35 또는 37항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트인 방법.
  39. 제35 또는 37항 중 어느 한 항에 있어서, 락테이트 에스테르가 라우릴 락테이트인 방법.
  40. 제35 또는 37항 중 어느 한 항에 있어서, 락테이트 에스테르가 에틸 락테이트인 방법.
  41. 제35 또는 37항 중 어느 한 항에 있어서, 락테이트 에스테르가 세틸 또는 미리스틸 락테이트인 방법.
  42. 제35 또는 37항 중 어느 한 항에 있어서, 락테이트 에스테르가 에틸 및 라우릴 락테이트인 방법.
  43. 제35 또는 37항 중 어느 한 항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며, 락테이트 에스테르가 에틸 락테이트 또는 라우릴 락테이트 또는 그의 혼합물인 방법.
  44. 제35 또는 37항 중 어느 한 항에 있어서, 약물이 벤조디아제핀, 항무스카린 제제, 에스트로겐, 안드로겐 또는 프로게스틴으로 이루어지는 군으로부터 선택되는 것인 방법.
  45. 제36 또는 37항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며, 글리세롤 모노라우레이트 및 락테이트 에스테르가 약물 함유 저장고의 각각 20중량% 및 12중량%를 이루어지는 것인 방법.
  46. 제35항에 있어서, 모노글리세리드가 글리세롤 모노라우레이트이며 글리세롤 모노라우레이트 및 락테이트 에스테르가 약물 및 투과 촉진제 혼합물의 각각 20중량% 및 12중량%를 이루는 것인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701610A 1993-09-29 1994-09-29 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer) KR960704578A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12949493A 1993-09-29 1993-09-29
US129494 1993-09-29
PCT/US1994/011120 WO1995009006A1 (en) 1993-09-29 1994-09-29 Monoglyceride/lactate ester permeation enhancer

Publications (1)

Publication Number Publication Date
KR960704578A true KR960704578A (ko) 1996-10-09

Family

ID=22440240

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019960701610A KR960704578A (ko) 1993-09-29 1994-09-29 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
KR1019960701611A KR960704579A (ko) 1993-09-29 1994-09-29 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin)

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019960701611A KR960704579A (ko) 1993-09-29 1994-09-29 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin)

Country Status (10)

Country Link
US (3) US5747065A (ko)
EP (2) EP0721349A1 (ko)
JP (3) JP3792252B2 (ko)
KR (2) KR960704578A (ko)
AT (1) ATE183926T1 (ko)
AU (2) AU679794B2 (ko)
CA (2) CA2165802A1 (ko)
DE (1) DE69420419T2 (ko)
NZ (2) NZ274711A (ko)
WO (2) WO1995009006A1 (ko)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
DE69401945T3 (de) * 1993-06-25 2004-09-02 Alza Corp., Palo Alto Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE69420419T2 (de) * 1993-09-29 1999-12-23 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
FR2735027B1 (fr) * 1995-06-07 1998-01-09 Alza Corp Compositions de renforcateurs de permeation d'agents a travers la peau, comprenant de l'acetate de lauryle et un monoglyceride
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
EP0909167B1 (en) * 1996-07-03 2002-10-30 Alza Corporation Drug delivery devices and process of manufacture
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
GB9618964D0 (en) * 1996-09-11 1996-10-23 Tillotts Pharma Ag Oral composition
DK0934078T3 (da) * 1996-10-24 2003-04-14 Alza Corp Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
WO1999032153A1 (en) 1997-12-22 1999-07-01 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
DE19812413C1 (de) * 1998-03-20 1999-06-10 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
EP1152749B1 (en) † 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2000064434A1 (fr) * 1999-04-26 2000-11-02 Lead Chemical Co., Ltd. Preparations percutanees contenant de l'oxybutynine
AU4808000A (en) * 1999-04-28 2000-11-10 Situs Corporation Drug delivery system
JP2003500354A (ja) 1999-05-20 2003-01-07 セプラコール， インク． Ｓ−オキシブチニンを用いる喘息の治療方法
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
NZ518723A (en) * 1999-11-24 2004-04-30 Agile Therapeutics Inc Improved transdermal contraceptive delivery system and process
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
WO2001080796A1 (en) 2000-04-26 2001-11-01 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20030026829A1 (en) * 2001-03-16 2003-02-06 Venkatraman Subramanian S. Transdermal administration of fentanyl and analogs thereof
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
EP1372605A2 (en) * 2001-03-27 2004-01-02 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
MXPA04012333A (es) * 2002-06-10 2005-02-25 Euro Celtique Sa Sistemas de colocacion de dispositivos de liberacion transdermica para prevenir el uso incorrecto de los agentes activos contenidos en los mismos.
PT1530469E (pt) * 2002-08-20 2009-05-19 Euro Celtique Sa Forma de dosagem transdérmica que compreende um agente activo, um sal e uma forma de base livre de um antagonista
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
DE10251256A1 (de) * 2002-11-04 2004-05-13 Novosis Ag Transdermales Wirkstoffabgabesystem für Oxybutynin
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
EP3025722B1 (en) 2003-10-03 2020-05-27 Thorn BioScience, LLC Process for the synchronization of ovulation for timed breeding without heat detection
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
US20060004094A1 (en) * 2004-07-02 2006-01-05 Agisim Gary R Composition and method for treating hemorrhoids and/or anorectal disorders
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
DK2216018T3 (da) 2004-10-21 2012-07-02 Durect Corp Transdermale leveringssystemer
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2007011763A2 (en) * 2005-07-15 2007-01-25 3M Innovative Properties Company Adhesive sheet and methods of use thereof
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
US8383149B2 (en) 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
US20070098772A1 (en) * 2005-09-23 2007-05-03 Westcott Tyler D Transdermal norelgestromin delivery system
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
CA2575398C (en) * 2006-02-02 2011-12-20 Omp, Inc. Methods of treating skin to enhance therapeutic treatment thereof
JP2009528990A (ja) * 2006-02-13 2009-08-13 アヴィバ ドラッグ デリバリー システムズ スフェンタニルを含む接着性調製物およびそれを用いる方法
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MY154027A (en) * 2007-10-15 2015-04-30 Alza Corp Once-a-day replacement transdermal administration of fentanyl
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
DK2421545T3 (en) 2009-04-23 2018-03-12 Jbs United Animal Health Ii Llc PROCEDURE AND COMPOSITION TO SYNCHRONIZE THE TIME OF INSEMINATION.
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9834719B2 (en) * 2010-11-30 2017-12-05 Schlumberger Technology Corporation Methods for servicing subterranean wells
US9950952B2 (en) 2010-11-30 2018-04-24 Schlumberger Technology Corporation Methods for servicing subterranean wells
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN104994865A (zh) 2012-11-28 2015-10-21 杰碧斯联合动物健康第二有限责任公司 用于同步小母猪的授精时间的方法
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP3842419B1 (en) 2013-02-28 2024-04-03 Journey Medical Corporation Method of making threo glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
CA2925374A1 (en) * 2013-10-01 2015-04-09 Novartis Ag Combination
CN110433291B (zh) 2013-10-03 2023-04-28 博世健康爱尔兰有限公司 稳定的艾菲康唑组合物
CA2931144C (en) 2013-11-22 2020-02-04 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3242659A4 (en) 2015-01-09 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
CA2987766A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN109803649B (zh) * 2016-10-11 2022-10-21 久光制药株式会社 含有奥昔布宁的透皮吸收制剂
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
AU2018358372A1 (en) * 2017-10-30 2020-05-28 Kaken Pharmaceutical Co., Ltd. External preparation for treating trichophytosis unguium
EP3705123A4 (en) 2017-10-30 2021-08-04 Teikoku Seiyaku Co., Ltd. TRANSDERMALLY ADMINISTRATIVE PREPARATION
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3527864A (en) * 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US4116956A (en) * 1968-11-05 1978-09-26 Takeda Chemical Industries, Ltd. Benzodiazepine derivatives
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3987052A (en) * 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3903256A (en) * 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) * 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) * 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
US4508726A (en) * 1982-09-16 1985-04-02 The Upjohn Company Treatment of panic disorders with alprazolam
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4710497A (en) * 1983-05-20 1987-12-01 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering physiologically active agents
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US4590190A (en) * 1983-07-01 1986-05-20 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4588739A (en) * 1984-03-02 1986-05-13 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4683231A (en) * 1984-03-02 1987-07-28 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4783456A (en) * 1984-03-02 1988-11-08 Research Foundation For Mental Hygiene, Inc. Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4663454A (en) * 1985-04-17 1987-05-05 The Upjohn Company Process to prepare α-chloroalprazolam
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4685913A (en) * 1985-05-24 1987-08-11 Professional Care Products, Inc. External single-use catheter
JPS61293911A (ja) * 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US4666903A (en) * 1985-08-13 1987-05-19 Yale University Novel use of benzodiazepine antagonist
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
DE3767615D1 (de) * 1986-03-10 1991-02-28 Kurt Burghart Pharmazeutikum sowie verfahren zu seiner herstellung.
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4876249A (en) * 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (ko) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
JPH0720866B2 (ja) * 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5017575A (en) * 1987-06-09 1991-05-21 Golwyn Daniel H Treatment of immunologically based disorders, specifically Crohn's disease
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins
US4814183A (en) * 1987-08-31 1989-03-21 Merck & Co., Inc. Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4925844A (en) * 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
JP2794022B2 (ja) * 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US4981468A (en) * 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5246949A (en) * 1989-12-06 1993-09-21 Sansho Co., Ltd. Preparation for endermism containing dopamine derivatives
JPH03236317A (ja) 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
MX9202350A (es) * 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
WO1993023025A1 (en) * 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
DE69420419T2 (de) * 1993-09-29 1999-12-23 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern

Also Published As

Publication number Publication date
NZ274711A (en) 1996-11-26
JP2006117688A (ja) 2006-05-11
KR960704579A (ko) 1996-10-09
NZ275615A (en) 1996-11-26
AU679793B2 (en) 1997-07-10
CA2165802A1 (en) 1995-04-06
AU679794B2 (en) 1997-07-10
DE69420419T2 (de) 1999-12-23
AU7964794A (en) 1995-04-18
JP3792252B2 (ja) 2006-07-05
DE69420419D1 (de) 1999-10-07
ATE183926T1 (de) 1999-09-15
EP0721348A1 (en) 1996-07-17
CA2167526A1 (en) 1995-04-06
US5750137A (en) 1998-05-12
WO1995009006A1 (en) 1995-04-06
EP0721349A1 (en) 1996-07-17
US5686097A (en) 1997-11-11
JP3688293B2 (ja) 2005-08-24
JPH09505278A (ja) 1997-05-27
EP0721348B1 (en) 1999-09-01
AU7924994A (en) 1995-04-18
US5747065A (en) 1998-05-05
WO1995009007A1 (en) 1995-04-06
JPH09505279A (ja) 1997-05-27

Similar Documents

Publication Publication Date Title
KR960704578A (ko) 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
EP2214643B1 (en) Transdermal delivery system for hormones and steroids
AU710760B2 (en) Drug delivery compositions for improved stability of steroids
CA2221096C (en) Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
JP2011502172A5 (ko)
AU670273B2 (en) Administration system for estradiol
CA2012875C (en) Skin permeation enhancer compositions
US5028431A (en) Article for the delivery to animal tissue of a pharmacologically active agent
DE4405898A1 (de) Transdermale therapeutische Systeme enthaltend Sexualsteroide
JPH01165529A (ja) 皮膚透過促進剤としてグリセロールモノオレエートを用いる治療系
KR100543351B1 (ko) 산에불안정한약물의경피전달을위한조성물
Briggs Lysosomal enzyme activation by steroid hormones in vivo
WO1995005137A1 (en) Transdermal delivery system using a combination of permeation enhancers
US20080171729A1 (en) Use Of A Steroid For Enhancement Of Skin Permeability
WO1997040792A1 (en) Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
DE4240806A1 (de) Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPS609727B2 (ja) 貼り付け用膏体
MXPA00002931A (en) Inhibition of crystallization in transdermal devices
KR930023040A (ko) 에스트라디올의 경피 투여용 접착 플라스터 및 그 제조 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid